199 related articles for article (PubMed ID: 25518732)
1. The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40.
Khong A; Cleaver AL; Fahmi Alatas M; Wylie BC; Connor T; Fisher SA; Broomfield S; Lesterhuis WJ; Currie AJ; Lake RA; Robinson BW
BMC Cancer; 2014 Dec; 14():969. PubMed ID: 25518732
[TBL] [Abstract][Full Text] [Related]
2. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ
J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767
[TBL] [Abstract][Full Text] [Related]
3. Agonistic anti-CD40 antibody therapy is effective against postoperative cancer recurrence and metastasis in a murine tumor model.
Khong A; Brown MD; Vivian JB; Robinson BW; Currie AJ
J Immunother; 2013 Sep; 36(7):365-72. PubMed ID: 23924788
[TBL] [Abstract][Full Text] [Related]
4. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.
Fransen MF; Sluijter M; Morreau H; Arens R; Melief CJ
Clin Cancer Res; 2011 Apr; 17(8):2270-80. PubMed ID: 21389097
[TBL] [Abstract][Full Text] [Related]
5. IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase.
Jackaman C; Lansley S; Allan JE; Robinson BW; Nelson DJ
Int Immunol; 2012 Jun; 24(6):357-68. PubMed ID: 22354912
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.
Ito H; Ando T; Arioka Y; Saito K; Seishima M
Immunology; 2015 Apr; 144(4):621-30. PubMed ID: 25322876
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ -independent resolution of treated-tumors and CD4+ -dependent systemic and memory responses.
Jackaman C; Nelson DJ
Cancer Immunol Immunother; 2012 Apr; 61(4):549-60. PubMed ID: 22002241
[TBL] [Abstract][Full Text] [Related]
8. The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma.
Cho JH; Lee HJ; Ko HJ; Yoon BI; Choe J; Kim KC; Hahn TW; Han JA; Choi SS; Jung YM; Lee KH; Lee YS; Jung YJ
Oncotarget; 2017 Apr; 8(15):24932-24948. PubMed ID: 28212561
[TBL] [Abstract][Full Text] [Related]
9. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.
Sandin LC; Orlova A; Gustafsson E; Ellmark P; Tolmachev V; Tötterman TH; Mangsbo SM
Cancer Immunol Res; 2014 Jan; 2(1):80-90. PubMed ID: 24778163
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice.
Ito H; Ando T; Ogiso H; Arioka Y; Seishima M
Cancer Immunol Immunother; 2015 Apr; 64(4):429-36. PubMed ID: 25567751
[TBL] [Abstract][Full Text] [Related]
11. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN.
Ahonen CL; Doxsee CL; McGurran SM; Riter TR; Wade WF; Barth RJ; Vasilakos JP; Noelle RJ; Kedl RM
J Exp Med; 2004 Mar; 199(6):775-84. PubMed ID: 15007094
[TBL] [Abstract][Full Text] [Related]
12. Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance.
Thatcher TH; Luzina I; Fishelevich R; Tomai MA; Miller RL; Gaspari AA
J Invest Dermatol; 2006 Apr; 126(4):821-31. PubMed ID: 16439962
[TBL] [Abstract][Full Text] [Related]
13. Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma.
Kruklitis RJ; Singhal S; Delong P; Kapoor V; Sterman DH; Kaiser LR; Albelda SM
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):123-30. PubMed ID: 14752422
[TBL] [Abstract][Full Text] [Related]
14. Transcutaneous immunization with CD40 ligation boosts cytotoxic T lymphocyte mediated antitumor immunity independent of CD4 helper cells in mice.
Bialojan A; Sohl J; Rausch J; Aranda Lopez P; Denny M; Langguth P; Hartmann AK; Yagita H; Probst HC; Schild H; Radsak MP
Eur J Immunol; 2019 Nov; 49(11):2083-2094. PubMed ID: 31393597
[TBL] [Abstract][Full Text] [Related]
15. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer.
Dewan MZ; Vanpouille-Box C; Kawashima N; DiNapoli S; Babb JS; Formenti SC; Adams S; Demaria S
Clin Cancer Res; 2012 Dec; 18(24):6668-78. PubMed ID: 23048078
[TBL] [Abstract][Full Text] [Related]
16. CD4
Doorduijn EM; Sluijter M; Salvatori DC; Silvestri S; Maas S; Arens R; Ossendorp F; van der Burg SH; van Hall T
Cancer Immunol Res; 2017 Aug; 5(8):642-653. PubMed ID: 28637878
[TBL] [Abstract][Full Text] [Related]
17. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma.
Anraku M; Tagawa T; Wu L; Yun Z; Keshavjee S; Zhang L; Johnston MR; de Perrot M
J Immunol; 2010 Jul; 185(2):956-66. PubMed ID: 20548032
[TBL] [Abstract][Full Text] [Related]
18. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery.
Thomsen LL; Topley P; Daly MG; Brett SJ; Tite JP
Vaccine; 2004 Apr; 22(13-14):1799-809. PubMed ID: 15068864
[TBL] [Abstract][Full Text] [Related]
19. CD40-activated B cells contribute to mesothelioma tumor regression.
Jackaman C; Cornwall S; Graham PT; Nelson DJ
Immunol Cell Biol; 2011 Feb; 89(2):255-67. PubMed ID: 20628372
[TBL] [Abstract][Full Text] [Related]
20. Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection.
Warger T; Rechtsteiner G; Schmid B; Osterloh P; Schild H; Radsak MP
Clin Rev Allergy Immunol; 2007 Feb; 32(1):57-66. PubMed ID: 17426361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
